Enhanced Methods for the Prevention and Treatment of Hearing Loss

Publication ID: 24-11857551_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Methods for the Prevention and Treatment of Hearing Loss,” Published Technical Disclosure No. 24-11857551_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857551_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,551.

Summary of the Inventive Concept

The present inventive concept discloses novel methods and compositions for preventing and treating hearing loss caused by chemotherapeutic agents or noise exposure, overcoming the limitations of existing treatments by enhancing the protective effects of chaetocin on inner ear cells.

Background and Problem Solved

Hearing loss is a significant health problem, particularly for cancer patients undergoing chemotherapy. The original patent disclosed methods for preventing and treating hearing loss using chaetocin. However, these methods have limitations, such as limited bioavailability and lack of targeted delivery to the inner ear cells. The present inventive concept addresses these limitations by introducing novel combinations, formulations, and delivery systems that enhance the protective effects of chaetocin.

Detailed Description of the Inventive Concept

The present inventive concept comprises novel methods and compositions that improve the prevention and treatment of hearing loss. One embodiment is a system combining chaetocin with a second therapeutic agent that enhances its protective effect on inner ear cells. Another embodiment involves administering chaetocin in a liposomal formulation to target the inner ear cells, reducing ototoxicity of chemotherapeutic agents. Additionally, a composition comprising chaetocin and a synergistic agent that enhances its bioavailability in the inner ear is disclosed. Furthermore, a method for treating hearing loss caused by noise exposure using chaetocin in combination with an antioxidant agent is presented. Finally, a device for delivering chaetocin to the inner ear, comprising a cochlear implant and a reservoir, is disclosed.

Novelty and Inventive Step

The present inventive concept introduces novel combinations, formulations, and delivery systems that enhance the protective effects of chaetocin on inner ear cells, overcoming the limitations of the original patent. The new claims provide a significant improvement over the existing methods, offering better efficacy, targeted delivery, and reduced ototoxicity.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include using different therapeutic agents, formulations, or delivery systems. For example, using nanoparticles or micelles for targeted delivery, or combining chaetocin with other antioxidants or anti-inflammatory agents. Additionally, the inventive concept could be adapted for treating other types of hearing loss, such as age-related hearing loss.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the pharmaceutical and medical device industries, particularly in the areas of oncology and otolaryngology. The market for hearing loss treatments is substantial, and the inventive concept's enhanced efficacy and reduced ototoxicity make it an attractive solution for patients and healthcare providers.

Field of Art

Pharmaceutical and medical treatments for hearing loss, specifically focusing on otoprotective interventions for chemotherapy-induced and noise-induced hearing damage, requiring expertise in pharmacology, cellular biology, and drug delivery systems

Person of Ordinary Skill (PHOSITA) Profile

A researcher or medical professional with advanced training in pharmacology, with knowledge of inner ear cellular mechanisms, drug formulation techniques, and experience in developing protective interventions for ototoxic conditions

Obviousness Rationale

A person having ordinary skill would recognize that the source patent's disclosure of chaetocin as a hearing loss treatment provides a clear foundation for exploring enhanced delivery methods and combinatorial approaches. The PTD's variations represent predictable extensions of the original patent's core concept, utilizing standard pharmaceutical techniques like liposomal delivery and combination therapy that are well-established in the field of drug development. These modifications would be considered routine optimization strategies by a skilled practitioner seeking to improve the efficacy and targeted delivery of the original chaetocin treatment method.

Obvious Combinations & Variations

Source Patent Element
Method of administering chaetocin to prevent hearing loss caused by chemotherapeutic agents
PTD Variation
Administering chaetocin in a liposomal formulation to enhance targeted delivery to inner ear cells
Obviousness Reasoning
Liposomal drug delivery is a known technique for improving cellular targeting and bioavailability, representing a predictable modification that a skilled practitioner would find obvious for enhancing drug efficacy
Source Patent Element
Protecting inner ear cells from chemotherapy-induced damage
PTD Variation
Combining chaetocin with a second therapeutic agent that enhances its protective effect
Obviousness Reasoning
Combination therapy is a standard approach in pharmaceutical development, and a PHOSITA would recognize the potential benefits of synergistic drug interactions to improve treatment outcomes
Source Patent Element
Treatment of hearing loss caused by chemotherapeutic agents
PTD Variation
Extending treatment method to include noise-induced hearing loss with antioxidant combination
Obviousness Reasoning
Recognizing common cellular mechanisms of damage across different hearing loss types, a skilled practitioner would find it obvious to adapt the treatment approach to related pathological conditions
Source Patent Element
Method of administering chaetocin to prevent hearing loss
PTD Variation
Developing a cochlear implant device with controlled chaetocin release mechanism
Obviousness Reasoning
Integrated drug delivery systems are a known technological solution for targeted and controlled medication administration, representing a predictable engineering modification
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857551, the variations disclosed herein would be considered obvious to a person having ordinary skill in the art of pharmaceutical interventions for hearing loss. The proposed modifications represent routine optimization strategies utilizing standard pharmaceutical techniques, including targeted drug delivery, combination therapy, and controlled release mechanisms, which would be apparent to a skilled practitioner seeking to improve the efficacy of the original chaetocin-based hearing loss treatment method.

Original Patent Information

Patent NumberUS 11,857,551
TitleMethods for the prevention and treatment of hearing loss
Assignee(s)Ting Therapeutics LLC